共刺激受体:肿瘤免疫疗法的潜在靶点

doi:10.11904/j.issn.1002-3070.2021.05.010

Abstract

Abstract: Co-stimulatory receptors on the surface of immune cells play important role in the activation,proliferation and effectors' function of immune cells.In tumors,co-stimulatory receptors can be activated by specific agonistic monoclonal antibodies to enhance the effectors' function of immune cells,promote the killing of tumor cells,inhibit tumor growth,and can be used as a target for anti-tumor immunotherapy.This article reviews the role of several co-stimulatory receptors in the physiological conditions,tumor immunology and anti-tumor immunotherapy.

Key words: Tumor, Co-stimulatory and inhibitory T-Cell receptors, Immunotherapy

CLC Number:

R730.51

ZHANG Weiming, SUN Jianping, ZHAO Yan. Co-stimulatory receptors:potential targets for tumor immunotherapy[J]. Journal of Practical Oncology, 2021, 35(5): 441-446.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.05.010

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I5/441

References

1 Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
2 Chen L,Flies DB.Molecular mechanisms of T cell co-stimulation and co-inhibition[J].Nat Rev Immunol,2013,13(4):227-242.
3 Toor SM,Sasidharan Nair V,Decock J,et al.Immune checkpoints in the tumor microenvironment[J].Semin Cancer Biol,2020,65:1-12.
4 Andrews LP,Yano H,Vignali DAA.Inhibitory receptors and ligands beyond PD-1,PD-L1 and CTLA-4:breakthroughs or backups[J].Nat Immunol,2019,20(11):1425-1434.
5 Knee DA,Hewes B,Brogdon JL.Rationale for anti-GITR cancer immunotherapy[J].Eur J Cancer,2016,67:1-10.
6 Vence L,Bucktrout SL,Fernandez Curbelo I,et al.Characterization and comparison of GITR expression in solid tumors[J].Clin Cancer Res,2019,25(21):6501-6510.
7 Zhu MMT,Burugu S,Gao D,et al.Evaluation of glucocorticoid-induced TNF receptor(GITR)expression in breast cancer and across multiple tumor types[J].Mod Pathol,2020,33(9):1753-1763.
8 Buzzatti G,Dellepiane C,Del Mastro L.New emerging targets in cancer immunotherapy:the role of GITR[J].ESMO Open,2020,4(Suppl 3):e000738.
9 Zappasodi R,Sirard C,Li Y,et al.Rational design of anti-GITR-based combination immunotherapy[J].Nat Med,2019,25(5):759-766.
10 Makkouk A,Chester C,Kohrt HE.Rationale for anti-CD137 cancer immunotherapy[J].Eur J Cancer,2016,54:112-119.
11 Glorieux C,Huang P.CD137 expression in cancer cells:regulation and significance[J].Cancer Commun(Lond),2019,39(1):70.
12 Schmohl JU,Nuebling T,Wild J,et al.Expression of 4-1BB and its ligand on blasts correlates with prognosis of patients with AML[J].J Investig Med,2016,64(8):1252-1260.
13 Grimmig T,Gasser M,Moench R,et al.Expression of tumor-mediated CD137 ligand in human colon cancer indicates dual signaling effects[J].Oncoimmunology,2019,8(12):e1651622.
14 Etxeberria I,Glez-Vaz J,Teijeira Á,et al.New emerging targets in cancer immunotherapy:CD137/4-1BB costimulatory axis[J].ESMO Open,2020,4(Suppl 3):e000733.
15 Buchan SL,Rogel A,Al-Shamkhani A.The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy[J].Blood,2018,131(1):39-48.
16 Nuebling T,Schumacher CE,Hofmann M,et al.The immune checkpoint modulator OX40 and its ligand OX40L in NK-cell immunosurveillance and acute myeloid leukemia[J].Cancer Immunol Res,2018,6(2):209-221.
17 Rothfelder K,Hagelstein I,Roerden M,et al.Expression of the immune checkpoint modulator OX40 in acute lymphoblastic leukemia is associated with BCR-ABL positivity[J].Neoplasia,2018,20(11):1150-1160.
18 Xie K,Xu L,Wu H,et al.OX40 expression in hepatocellular carcinoma is associated with a distinct immune microenvironment,specific mutation signature,and poor prognosis[J].Oncoimmunology,2018,7(4):e1404214.
19 He Y,Zhang X,Jia K,et al.OX40 and OX40L protein expression of tumor infiltrating lymphocytes in non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers[J].Transl Lung Cancer Res,2019,8(4):352-366.
20 Ramser M,Eichelberger S,Däster S,et al.High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy[J].BMC Cancer,2018,18(1):425.
21 Weixler B,Cremonesi E,Sorge R,et al.OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer[J].Oncotarget,2015,6(35):37588-37599.
22 Alves Costa Silva C,Facchinetti F,Routy B,et al.New pathways in immune stimulation:targeting OX40[J].ESMO Open,2020,5(1):e000573.
23 Starzer AM,Berghoff AS.New emerging targets in cancer immunotherapy:CD27(TNFRSF7)[J].ESMO Open,2020,4(Suppl 3):e000629.
24 Riether C,Schürch CM,Bührer ED,et al.CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia[J].J Exp Med,2017,214(2):359-380.
25 Chen D,Gerasimˇcik N,Camponeschi A,et al.CD27 expression and its association with clinical outcome in children and adults with pro-B acute lymphoblastic leukemia[J].Blood Cancer J,2017,7(6):e575.
26 Shan TT,Zhao X,Zhang Z,et al.Clinical significance of down-regulated CD70 and CD27 expression in poor prognosis of esophageal squamous cell carcinoma[J].Cancer Manag Res,2020,12:6909-6920.
27 Ge H,Mu L,Jin L,et al.Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM[J].Int J Cancer,2017,141(7):1434-1444.
28 Wensveen FM,Unger PP,Kragten NA,et al.CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load[J].J Immunol,2012,188(9):4256-4267.
29 Claus C,Riether C,Schürch C,et al.CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth[J].Cancer Res,2012,72(14):3664-3676.
30 Wasiuk A,Testa J,Weidlick J,et al.CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy[J].J Immunol,2017,199(12):4110-4123.
31 Burris HA,Infante JR,Ansell SM,et al.Safety and activity of varlilumab,a novel and first-in-class agonist anti-CD27 antibody,in patients with advanced solid tumors[J].J Clin Oncol,2017,35(18):2028-2036.
32 Blazquez JL,Benyamine A,Pasero C,et al.New insights into the regulation of γδ T cells by BTN3A and other BTN/BTNL in tumor immunity[J].Front Immunol,2018,9:1601.
33 Zocchi MR,Costa D,Venè R,et al.Zoledronate can induce colorectal cancer microenvironment expressing BTN3A1 to stimulate effector γδ T cells with antitumor activity[J].Oncoimmunology,2017,6(3):e1278099.
34 Payne KK,Mine JA,Biswas S,et al.BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells[J].Science,2020,369(6506):942-949.
35 Benyamine A,Loncle C,Foucher E,et al.BTN3A is a prognosis marker and a promising target for Vγ9Vδ2 T cells based-immunotherapy in pancreatic ductal adenocarcinoma(PDAC)[J].Oncoimmunology,2017,7(1):e1372080.
36 Zhu M,Yan C,Ren C,et al.Exome array analysis identifies variants in SPOCD1 and BTN3A2 that affect risk for gastric cancer[J].Gastroenterology,2017,152(8):2011-2021.
37 Benyamine A,Le Roy A,Mamessier E,et al.BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia[J].Oncoimmunology,2016,5(10):e1146843.
38 Laman JD,Claassen E,Noelle RJ.Functions of CD40 and its ligand,gp39(CD40L)[J].Crit Rev Immunol,2017,37(2-6):371-420.
39 Dimitrakopoulos FD,Kottorou AE,Antonacopoulou AG,et al.Expression of immune system-related membrane receptors CD40,RANK,BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients[J].J Clin Med,2019,8(5):741.
40 Werner JM,Kuhl S,Ulrich K,et al.Expression of CD40 correlates negatively with overall and progression-free survival of low-and high-grade gliomas[J].World Neurosurg,2019,130:17-25.
41 Matsumura Y,Hiraoka K,Ishikawa K,et al.CD40 expression in human esophageal squamous cell carcinoma is associated with tumor progression and lymph node metastasis[J].Anticancer Res,2016,36(9):4467-4475.
42 Vonderheide RH.CD40 agonist antibodies in cancer immunotherapy[J].Annu Rev Med,2020,71:47-58.
43 Vonderheide RH,Flaherty KT,Khalil M,et al.Clinical activity and immune modulation in cancer patients treated with CP-870,893,a novel CD40 agonist monoclonal antibody[J].J Clin Oncol,2007,25(7):876-883.
44 Bajor DL,Mick R,Riese MJ,et al.Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma[J].Oncoimmunology,2018,7(10):e1468956.
45 Segal NH,He AR,Doi T,et al.Phase I study of single-agent utomilumab(PF-05082566),a 4-1BB/CD137 agonist,in patients with advanced cancer[J].Clin Cancer Res,2018,24(8):1816-1823.
46 Gopal AK,Levy R,Houot R,et al.First-in-human study of utomilumab,a 4-1BB/CD137 agonist,in combination with rituximab in patients with follicular and other CD20⁺ non-hodgkin lymphomas[J].Clin Cancer Res,2020,26(11):2524-2534.

[1]	FU Yan¹, YAN Lili², WANG Chunyu², FU Fangmin², DONG Hua³. Analysis for the prevalence of malignant tumors in Qionghai city from 2010 to 2016 [J]. Journal of Practical Oncology, 2021, 35(5): 396-401.
[2]	SHANG Changquan¹, LI Guodong¹, WEI Jiufeng¹, LIU Ming². Research progress of MCM protein in digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(5): 431-435.
[3]	LONG Yuanhui, CHEN Xuesong. Research progress on the effect of psychological stress on immune cells in tumor microenvironment [J]. Journal of Practical Oncology, 2021, 35(5): 436-440.
[4]	ZHANG Lu, DONG Zhenkun, CUI Yan. Research progress of circulating tumor DNA in renal cancer [J]. Journal of Practical Oncology, 2021, 35(5): 447-451.
[5]	JIN Shengye, PANG Da. Research progress in the mechanism of oncolytic virus inducing tumor apoptosis and activating anti-tumor immunity [J]. Journal of Practical Oncology, 2021, 35(5): 462-467.
[6]	FAN Lin, TIAN Linli, LIU Ming. Research and development of single-cell sequencing technology in head and neck malignant tumors [J]. Journal of Practical Oncology, 2021, 35(5): 472-475.
[7]	LIU Yanyu, LI Daojuan, LIANG Di, SHI Jin, JIN Jing, SHAN Baoen, HE Yutong. An analysis of the incidence and mortality of esophageal cancer in Hebei cancer registration area from 2011 to 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 314-320.
[8]	WANG Qin, LIN Ling, CAI Bo, TAO Changyu, WU Ming, HAN Renqiang, LUO Pengfei, YU Hao, MIAO Weigang, ZHOU Jinyi. Epidemic status of brain and nervous system tumors in Jiangsu province in 2015 and trend analysis from 2006 to 2015 [J]. Journal of Practical Oncology, 2021, 35(4): 321-326.
[9]	WU Jing, CUI Wangfei, CAO Ling, GUO Xuerong, MA Zhaohui, WANG Xinchen, ZHANG Ruifeng, ZHANG Yongzhen. Analysis for the incidence and death of upper gastrointestinal cancer in the cancer registration areas of Shanxi province in 2016 [J]. Journal of Practical Oncology, 2021, 35(4): 327-331.
[10]	DONG Hua, WANG Dingbin, HUA Jing, FAN Kangqiong, MA Nannan, WANG Xingren. Analysis for the incidence and death of malignant tumors in Hainan cancer registry,2016 [J]. Journal of Practical Oncology, 2021, 35(4): 344-350.
[11]	LIU Shuangqing, CHE Dehai, MENG Qingwei. 5-Hydroxymethylcytosine and tumor [J]. Journal of Practical Oncology, 2021, 35(4): 386-390.
[12]	CHEN Lili, LIU Yuqin, DING Gaoheng, SU Haixiang. Epidemic situation about prevention and control of malignant tumor in Gansu province [J]. Journal of Practical Oncology, 2021, 35(3): 254-257.
[13]	MA Mingrui, LIAN Jie, LIU Chao, LOU Changjie, ZHANG Yanqiao. Exploration of “immunotherapy moving forward” for digestive system tumors [J]. Journal of Practical Oncology, 2021, 35(3): 258-262.
[14]	LI Min, RAN Li, CHANG Jianying. Application of imaging technology in image-guided brachytherapy for cervical cancer [J]. Journal of Practical Oncology, 2021, 35(3): 263-267.
[15]	SHI Yuanyang, LIU Jiaren. Research progress in anticancer activity of β-ionone [J]. Journal of Practical Oncology, 2021, 35(3): 268-272.

Co-stimulatory receptors:potential targets for tumor immunotherapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments